Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2025-08-26 Interim / Quarterly Rep…
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
2025年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is a semi-annual report (half-year report) containing detailed financial data, business operations, management assurances, and other substantive information about the company's performance for the reporting period ending June 30, 2025. It includes financial figures, business model descriptions, shareholder information, and notes on asset restrictions. The document is over 6,000 characters, indicating it is a full report rather than a brief announcement. The presence of comprehensive financial data and management discussion confirms it is an Interim / Quarterly Report (IR). H1 2025
2025-08-26 Chinese
2025年半年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the storage, management, and actual use of funds raised in the first half of 2025 by 江西新赣江药业股份有限公司. It details the amount of funds raised, their storage in specific bank accounts, usage in various projects, and compliance with regulatory requirements. The document includes detailed financial figures related to fundraising, usage, and cash management, as well as references to regulatory approvals and audit reports. The content focuses specifically on the management and use of capital raised through a public offering, rather than a general financial performance report or earnings release. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is over 6,000 characters and contains substantive financial data and analysis related to fundraising and capital use, not merely an announcement or certification. Therefore, the appropriate classification is CAP.
2025-08-26 Chinese
关于拟注销一家三级子公司的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the planned cancellation (注销) of a third-level subsidiary company by Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It includes details about the subsidiary, the board resolution approving the cancellation, and the impact on the company. There is no financial data, no report attached or referenced as published, and no mention of financial results or regulatory filings. The document is a corporate announcement about a management decision related to company structure and subsidiaries. This fits best under Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2025-08-26 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is a detailed financial and operational report for the half-year period ending June 30, 2025, as indicated by the '报告期' definition and multiple references to '半年度报告' (half-year report). It includes comprehensive sections such as company overview, accounting data, financial indicators, business operations, risk factors, and detailed financial statements with actual financial data and analysis. The document explicitly states it is a '半年度报告' (half-year report) and contains substantive financial data, including income, expenses, assets, liabilities, and cash flow information. It is not a brief announcement or a certification letter but a full interim financial report. Therefore, the appropriate classification is 'Interim / Quarterly Report' (IR). H1 2025
2025-08-26 Chinese
2025年第二次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 second extraordinary shareholders' meeting of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, voting results on various proposals, and legal opinions confirming the legality and validity of the meeting and its resolutions. The content focuses on the official voting results and decisions made by shareholders during the meeting, which aligns with the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not a report itself but a formal announcement of voting outcomes from a shareholders' meeting, and it is not an AGM Information presentation or a Proxy Solicitation. The length is under 5,000 characters but contains substantive voting results, so it is not a mere report publication announcement or regulatory filing. Therefore, the correct classification is DVA with high confidence.
2025-08-25 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 江西新赣江药业股份有限公司 dated August 2025. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, capital changes, shareholder meetings, and governance rules. It references compliance with Chinese company law, securities law, and stock exchange rules. The content is a comprehensive governance document outlining internal rules and corporate governance practices rather than a financial report or announcement. It is not an Annual Report, Interim Report, or any financial statement. It is not a notice of voting results, nor a management change announcement. It is not a proxy statement or remuneration report. The document fits the definition of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices.
2025-08-25 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.